We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Análise de custo-efetividade do uso de inibidores da via de sinalização mTOR x micofenolato em receptores de transplante renal sem profilaxia para citomegalovírus.
- Authors
Rodrigues Magacho, Flávia Lícia; Chaoubah, Alfredo; Fernandes Ferreira, Gustavo; Côrtes Fernandes, Guilherme; Campos Tassi, Juliana Bastos; Sardão Colares, Vinícius; Resende Avelino, Natália; Jorge Gonçalves, Patrícia
- Abstract
Objective: Evaluate the cost-effectiveness of immunosuppressive regimens used in kidney transplant recipients at the Santa Casa de Misericórdia, Hospital in Juiz de Fora, MG, compared with basiliximab, mycophenolate sodium, tacrolimus and prednisone (Group 1 = 93 patients) with the association of thymoglobulin, everolimus, tacrolimus and prednisone (Group 2 = 91 patients). Methods: For the pharmacoeconomic analysis, the Decision Tree model was used, developed in the TreeAge Suite 2011 software. A real cohort of patients undergoing kidney transplantation between January 2013 and March 2017 was considered, they were followed up for a period of 1 year, where the clinical benefits were measured, as well as the associated costs, from the perspective of the Unified Health System. The costing method used was the botton-up. Cost-effectiveness thresholds equivalent to 1 PIB per capita and 1 to 3 PIB were adopted, considering the year 2017. Results: Regard to survival, the ICER was R$ 214,234.12 for 1 year of life gained. Regarding adverse events, the ICER was R$ 43,682.98 for 1 year with no incidence of adverse events. Conclusions: Evaluating survival and incidence of adverse events, thymoglobulin+everolimus is not considered cost-effective in relation to the regimen containing basiliximab+mycophenolate sodium in the face of an cost-effectiveness threshold of 1 PIB per capita. However, when adopting threshold up to 3 GDP per capita, the regimen containing thymoglobulin+everolimus is cost-effective, exceeding about 38% PIB per capita.
- Subjects
JUIZ de Fora (Brazil); BASILIXIMAB; KIDNEY transplantation; DECISION trees; TACROLIMUS; HEART transplant recipients; PER capita; ALLOCATION of organs, tissues, etc.; ORGAN transplant waiting lists
- Publication
JBES: Brazilian Journal of Health Economics / Jornal Brasileiro de Economia da Saúde, 2022, Vol 14, p162
- ISSN
2175-2095
- Publication type
Article
- DOI
10.21115/JBES.v14.Suppl2.p162-72